Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Tight Glucose Control Slashes Heart Risks

By HospiMedica staff writers
Posted on 22 Jun 2005
Frequent self-monitoring of blood glucose that guides the use of at least three insulin injections a day can lower the risk of heart events by about 50% in people with type 1 diabetes, according to the results of a study presented at the annual meeting of the American Diabetes Association in San Diego (ADA, CA, USA) in June 2005.

A multicenter study called the Diabetes Control and Complications Trial (DCCT) found in 1993 that intensive glucose control greatly reduces the eye, nerve, and kidney damage of type 1 diabetes as well as the risk of atherosclerosis. More...
Now researchers have found that what is more impressive is the long-lasting value of tight glucose control.

In the new results announced at the ADA meeting, involving 1,375 volunteers who continued to participate in the study, the intensely treated patients had less than half the number of cardiovascular events found in the conventionally treated group of patients. Cardiovascular events included heart attacks, stroke, angina, coronary artery disease requiring angioplasty, or coronary bypass surgery.

"The risk of heart disease is about 10 times higher in people with type 1 diabetes than in people without diabetes. It's now clear that high blood glucose levels contribute to the development of heart disease,” observed David Nathan, M.D., of Massachusetts General Hospital (Boston, USA), co-chair of the DCCT trial and the EDIC (Epidemiology of Diabetes Interventions and Complications) study follow-up.

"There is a strong and growing body of evidence that everyone with diabetes gains from strict blood glucose control,” noted Catherine Cowie, Ph.D., who oversees EDIC for the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (Bethesda, MD, USA), which funded the studies.





Related Links:
Mass. General Hospital
NIDDK

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Adjustable Mobile Barrier
M-458
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.